237 related articles for article (PubMed ID: 30327311)
1. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.
Koshkin VS; Garcia JA; Reynolds J; Elson P; Magi-Galluzzi C; McKenney JK; Isse K; Bishop E; Saunders LR; Balyimez A; Rashid S; Hu M; Stephenson AJ; Fergany AF; Lee BH; Haber GP; Dowlati A; Gilligan T; Ornstein MC; Rini BI; Abazeed ME; Mian OY; Grivas P
Clin Cancer Res; 2019 Jan; 25(1):210-221. PubMed ID: 30327311
[TBL] [Abstract][Full Text] [Related]
2. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.
Burgess EF; Sanders JA; Livasy C; Symanowski J; Gatalica Z; Steuerwald NM; Arguello D; Brouwer CR; Korn WM; Grigg CM; Zhu J; Matulay JT; Clark PE; Heath EI; Raghavan D
Urol Oncol; 2022 Aug; 40(8):383.e1-383.e10. PubMed ID: 35662501
[TBL] [Abstract][Full Text] [Related]
4. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
[TBL] [Abstract][Full Text] [Related]
5. Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma.
Maimaiti A; Wang X; Hao Y; Jiang L; Shi X; Pei Y; Feng Z; Kasimu M
J Mol Neurosci; 2021 Aug; 71(8):1622-1635. PubMed ID: 33713320
[TBL] [Abstract][Full Text] [Related]
6. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Krytska K; Casey CE; Pogoriler J; Martinez D; Rathi KS; Farrel A; Berko ER; Tsang M; Sano RR; Kendsersky N; Erickson SW; Teicher BA; Isse K; Saunders L; Smith MA; Maris JM; Mossé YP
Cancer Res Commun; 2022 Jul; 2(7):616-623. PubMed ID: 36381237
[TBL] [Abstract][Full Text] [Related]
9. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
[TBL] [Abstract][Full Text] [Related]
10. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
11. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
[TBL] [Abstract][Full Text] [Related]
12. POU2F3-positive small cell carcinoma of the bladder: A clinicopathologic analysis of 4 cases and literature review.
Cai Z; Cheng X; Liao S; Zou W; Li L; Liu F; Huang W
Pathol Res Pract; 2024 May; 257():155296. PubMed ID: 38615507
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
14. Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma.
Xie H; Kaye FJ; Isse K; Sun Y; Ramoth J; French DM; Flotte TJ; Luo Y; Saunders LR; Mansfield AS
Oncologist; 2020 Sep; 25(9):810-817. PubMed ID: 32372416
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of Neuroendocrine-like Bladder Cancer.
Batista da Costa J; Gibb EA; Bivalacqua TJ; Liu Y; Oo HZ; Miyamoto DT; Alshalalfa M; Davicioni E; Wright J; Dall'Era MA; Douglas J; Boormans JL; Van der Heijden MS; Wu CL; van Rhijn BWG; Gupta S; Grivas P; Mouw KW; Murugan P; Fazli L; Ra S; Konety BR; Seiler R; Daneshmand S; Mian OY; Efstathiou JA; Lotan Y; Black PC
Clin Cancer Res; 2019 Jul; 25(13):3908-3920. PubMed ID: 30952638
[TBL] [Abstract][Full Text] [Related]
16. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
[TBL] [Abstract][Full Text] [Related]
17. Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
Matsuo K; Taniguchi K; Hamamoto H; Inomata Y; Komura K; Tanaka T; Lee SW; Uchiyama K
Cancer Sci; 2021 Aug; 112(8):2984-2992. PubMed ID: 34107132
[TBL] [Abstract][Full Text] [Related]
18. Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer: A retrospective study.
Wang J; Zhang K; Liu Z; Wang T; Shi F; Zhang Y; Su J; Jia Y
Medicine (Baltimore); 2018 Dec; 97(51):e13442. PubMed ID: 30572444
[TBL] [Abstract][Full Text] [Related]
19. DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.
Noor H; Whittaker S; McDonald KL
Genomics; 2022 Mar; 114(2):110289. PubMed ID: 35124175
[TBL] [Abstract][Full Text] [Related]
20. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
